Stephanie Lagarde
Overview
Explore the profile of Stephanie Lagarde including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
89
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fregona V, Bayet M, Bouttier M, Largeaud L, Hamelle C, Jamrog L, et al.
J Exp Med
. 2023 Nov;
221(1).
PMID: 37930337
B cell acute lymphoblastic leukemia (B-ALL) is a multistep disease characterized by the hierarchical acquisition of genetic alterations. However, the question of how a primary oncogene reprograms stem cell-like properties...
2.
Piedrafita A, Vergez F, Belliere J, Prades N, Colombat M, Huart A, et al.
J Clin Med
. 2022 Feb;
11(3).
PMID: 35160055
Large granular T-cell leukemia is a clonal hematological condition often associated with autoimmune disorders. Whether small-sized T-cell clones that are otherwise asymptomatic can promote immune kidney disorders remains elusive. In...
3.
Lafage-Pochitaloff M, Gerby B, Baccini V, Largeaud L, Fregona V, Prade N, et al.
Blood Adv
. 2021 Oct;
6(2):386-398.
PMID: 34638130
Myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis leading to peripheral cytopenias and in a substantial proportion of cases to acute...
4.
Bories P, Prade N, Lagarde S, Cabarrou B, Largeaud L, Plenecassagnes J, et al.
PLoS One
. 2020 Oct;
15(10):e0238795.
PMID: 33001991
Hypomethylating agents are a classical frontline low-intensity therapy for older patients with acute myeloid leukemia. Recently, TP53 gene mutations have been described as a potential predictive biomarker of better outcome...
5.
Laurent A, Siret A, Ignacimouttou C, Panchal K, Diop M, Jenni S, et al.
Clin Cancer Res
. 2020 Mar;
26(13):3307-3318.
PMID: 32220889
Purpose: Children with Down syndrome (constitutive trisomy 21) that develop acute lymphoblastic leukemia (DS-ALL) have a 3-fold increased likelihood of treatment-related mortality coupled with a higher cumulative incidence of relapse,...
6.
Jamrog L, Chemin G, Fregona V, Coster L, Pasquet M, Oudinet C, et al.
Proc Natl Acad Sci U S A
. 2018 Sep;
115(41):10357-10362.
PMID: 30257940
is a well-known haploinsufficient tumor suppressor gene in human B-cell precursor acute lymphoblastic leukemia (B-ALL) and is involved in various chromosomal translocations that fuse a part of PAX5 with other...
7.
Cresson C, Peron S, Jamrog L, Rouquie N, Prade N, Dubois M, et al.
Oncotarget
. 2018 Sep;
9(67):32841-32854.
PMID: 30214688
Pax5 is the guardian of the B cell identity since it primes or enhances the expression of B cell specific genes and concomitantly represses the expression of B cell inappropriate...
8.
Dumas A, Lagarde S, Laflamme C, Pouliot M
J Cell Mol Med
. 2011 Aug;
16(6):1274-85.
PMID: 21854541
Oncostatin M (OSM) is a pleiotropic cytokine of the IL-6 family and displays both pro-inflammatory and anti-inflammatory activities. We studied the impact of OSM on the gene activation profile of...
9.
Russell F, Zhan S, Dumas A, Lagarde S, Pouliot M, McDougall J
Pain
. 2011 Jan;
152(2):354-360.
PMID: 21238854
Proteinase-activated receptor-4 (PAR(4)) is a G-protein-coupled receptor activated by serine proteinases released during tissue repair and inflammation. We have previously shown that PAR(4) activation sensitises articular primary afferents leading to...
10.
Hollebecque A, Bouche O, Romano O, Scaglia E, Cattan S, Zerbib P, et al.
Chemotherapy
. 2010 Jun;
56(3):234-8.
PMID: 20551640
Backgrounds: The combination gemcitabine-oxaliplatin (GEMOX) is frequently used in patients with advanced biliary tract carcinoma (BTC). However, this is only based on phase II studies performed in selected patients.We assessed...